Premium
Human pharmacology and abuse potential of meptazinol
Author(s) -
Johnson Rolley E,
Jasinski Donald R
Publication year - 1987
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1987.52
Subject(s) - dysphoria , morphine , euphoriant , anesthesia , clinical pharmacology , placebo , opioid , pharmacology , crossover study , medicine , psychology , psychiatry , anxiety , alternative medicine , receptor , pathology
Meptazinol was assessed in nine opioid abusers according to a double‐blind, randomized, crossover design to determine if it produced typical morphine effects. A comparison of physiologic and subjective effects was made between morphine, 7.5, 15, and 30 mg, meptazinol, 70, 140, and 280 mg, and placebo. Both drugs constricted pupils. Meptazinol, 140 and 280 mg, decreased body temperature. Valid relative potency estimates of morphine to meptazinol were obtained for self‐reported liking, opiate symptoms, and pupillary constriction. Meptazinol did not increase euphoria or sedation scale scores but did increase dysphoria scale scores. In the therapeutic dose range, meptazinol produced miosis, morphine‐like identification and symptoms, limited liking, and some dysphoria. Dysphoria predominated at the 280 mg dose of meptazinol. From these data, it is concluded that meptazinol is not a typical morphine‐like drug and has limited abuse potential. Clinical Pharmacology and Therapeutics (1987) 41 , 426–433; doi: 10.1038/clpt.1987.52